A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Recruiting Clinical Trial

Official title:
A Phase 3, Randomized, Double-blind Study of H02 Plus CHOP Versus R-CHOP in Patients With Diffuse Large B-cell Lymphoma

Status Recruiting

Clinical Trial Summary

This trial is a Multicenter, randomized, double-blind, parallel, controlled, and equivalence phase Ⅲ study. Primary objective: The purpose is to compare the objective response rate of H02 (rituximab biosimilar) plus CHOP and rituximab plus CHOP, as first-line treatment of diffuse large B-cell lymphoma. Secondary objective: The purpose is to compare the safety of H02 combined with CHOP regimen and rituximab injection (Rituximab®) combined with CHOP regimen in the treatment of newly treated diffuse large B-cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05040906
Study type	Interventional
Source	Shandong New Time Pharmaceutical Co., LTD
Contact	jianfeng zhou, Doctor
Phone	13627284963
Email	jfzhoutj@163.com
Status	Recruiting
Phase	Phase 3
Start date	October 13, 2020
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01894971` - The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube	Phase 3
Recruiting	`NCT05969951` - VTE Risk Prevention System Based on Big Data Analysis and Multimodule System
Recruiting	`NCT05376111` - Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients	Phase 2